Pliant Therapeutics to Showcase Advances in Pulmonary Disease Research at 2025 American Thoracic Society International Conference

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

San Francisco, CA, April 7, 2025 – Pliant Therapeutics, a biotechnology company focused on developing novel therapies for the treatment of fibrotic diseases, announced today that it will be presenting at the 2025 American Thoracic Society (ATS) International Conference.

The presentations will highlight the company's progress in the development of its lead candidate, PTG-300, a monoclonal antibody targeting the fibrotic protein, fibroblast growth factor 1 (FGF1). The data to be presented demonstrate the potential of PTG-300 to treat idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease characterized by scarring of the lungs.

"We are excited to share our latest findings on PTG-300 at the ATS conference," said Dr. John Freund, Chief Scientific Officer of Pliant Therapeutics. "Our data suggest that PTG-300 has the potential to be a game-changer in the treatment of IPF and other fibrotic diseases."

The presentations will take place on May 18-20, 2025, in Philadelphia, PA. For more information on the conference, please visit the ATS website at www.thoracic.org.

About Pliant Therapeutics Pliant Therapeutics is a biotechnology company focused on developing novel therapies for the treatment of fibrotic diseases. The company's lead candidate, PTG-300, is a monoclonal antibody targeting the fibrotic protein, FGF1. Pliant Therapeutics is headquartered in San Francisco, CA.